Section 5 - Management of Anemia
Published online by Cambridge University Press: 18 April 2018
- Type
- Chapter
- Information
- AnemiaPathophysiology, Diagnosis, and Management, pp. 216 - 228Publisher: Cambridge University PressPrint publication year: 2017
References
References
Bothwell, TH. Overview and mechanisms of iron regulation. Nutr Rev. 1995; 53:237–245.CrossRefGoogle ScholarPubMed
Teucher, B, Olivares, M, Cori, H. Enhancers of iron absorption: ascorbic acid and other organic acids. Int J Vitam Nutr Res. 2004; 74:403–419.CrossRefGoogle ScholarPubMed
Cancelo-Hidalgo, MJ, Castelo-Branco, C, Palacios, S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013; 29:291–303.Google Scholar
Melamed, N, Ben-Haroush, A, Kaplan, B, et al. Iron supplementation in pregnancy—does the preparation matter? Arch Gynecol Obstet. 2007; 276:601–604.Google Scholar
Rimon, E, Kagansky, N, Kagansky, M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005; 118:1142–1147.CrossRefGoogle ScholarPubMed
Auerbach, M, Ballard, H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010; 2010:338–347.CrossRefGoogle ScholarPubMed
Chertow, GM, Mason, PD, Vaage-Nilsen, O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21:378–382.CrossRefGoogle ScholarPubMed
Fernández-Bañares, F, Monzón, H, Forné, M. A short review of malabsorption and anemia. World J Gastroenterol. 2009; 15:4644–4652.CrossRefGoogle Scholar
Gafter-Gvili, A, Rozen-Zvi, B, Vidal, L. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013; 52:18–29.CrossRefGoogle ScholarPubMed
Steensma, DP, Sloan, JA, Dakhil, SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011; 29:97–105.Google Scholar
Henry, DH, Dahl, NV, Auerbach, M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12:231–242.Google Scholar
Albaramki, J, Hodson, EM, Craig, JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1:CD007857.Google Scholar
Macdougall, IC, Padhi, D, Jang, G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant. 2007; 22 Suppl 4:iv2–iv9.CrossRefGoogle ScholarPubMed
Palmer, SC, Navaneethan, SD, Craig, JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153:23–33.CrossRefGoogle ScholarPubMed
Kansagara, D, Dyer, E, Englander, H, et al. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med. 2013; 159:746–757.Google Scholar
Cody, J, Daly, C, Campbell, M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005; 3:CD003266.Google Scholar
Lau, JH, Gangji, AS, Rabbat, CG, et al. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010; 25:4002–4009.CrossRefGoogle ScholarPubMed
Tonia, T, Mettler, A, Robert, N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12:CD003407.Google Scholar
Smith, RE Jr., Aapro, MS, Ludwig, H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008; 26:1040–1050.CrossRefGoogle ScholarPubMed
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia (V.2.2014). Available at www.nccn.org/professionals/physician_gls/pdf/anemia.pdf (Accessed December 11, 2013).Google Scholar
Goodnough, LT, Monk, TG, Andriole, GL. Erythropoietin therapy. N Engl J Med. 1997; 27:933–938.Google Scholar
References
Schilling, RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis – a personal view. Br J Hematol. 2009; 145:728–732.CrossRefGoogle ScholarPubMed
Schilling, RF, Gangnon, RE, Traver, MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008; 6:1289–1295.CrossRefGoogle ScholarPubMed
Jaı¨s, X, Ioos, V, Jardim, C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax. 2005; 60:1031–1034.Google Scholar
Hoeper, MM, Neidermeyer, J, Hoffmeyer, F, et al. Pulmonary hypertension after splenectomy? Ann Intern Med. 1999; 130:506–509.Google Scholar
Buesing, KL et al. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatric Surg. 2011:46(1):178–183.Google Scholar
Seims, AD et al. Partial versus total splenectomy in children with hereditary spherocytosis. Surgery. 2013; 154(4):849–855.CrossRefGoogle ScholarPubMed
Lechner, K, Jager, U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116(11):1831–1838.CrossRefGoogle Scholar
Li, Y et al. Splenectomy in the management of Evans syndrome in adult: Long-term follow-up of 32 patients. Surgical Practice. 2014; 18(1):15–22.CrossRefGoogle Scholar
Jaime-Perez, JC, Rodriguez-Martiniez, M, Gomez-de-Leon, A, Tarin-Arzaga, L, Gomez-Almaguer, D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp. 2013; 61:385–395.Google Scholar
Akpek, G, McAneny, D, Weintraub, L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999; 61:98–102.Google Scholar
Graziano, JH, Piomelli, S, Hilgartner, M, et al. Chelation therapy in beta thallasemia major: the role of splenectomy in achieving iron balance. J Pediatriacs. 1981; 99(5):695–699.Google Scholar
Casale, M, Cinque, P, Ricchi, P, Constantini, S, Spasiano, A, Prossomariti, L, Minelli, S, Frega, V, Filosa, A. Effect of splenectomy on iron balance in patients with B-thalassemia major: a long term follow-up. Eur Hematol. 2013; 91(69–73):__.Google Scholar
Taher, AT, Mussallam, KM, Karimi, M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010; 115(10):1886–1892.Google Scholar
Rashba, EJ, Rowe, JM, Packman, CH. Treatment of the neutropenia of Felty Syndrome. Blood Rev. 1996; 10:177–184.CrossRefGoogle ScholarPubMed
Mesa, RA, Nagorney, DS, Schwager, S, Allred, J, Tefferi, A. Palliative goals, patient selection, and perioperative platelet management; outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006; 107(2):361–370.Google Scholar
Cervantes, F. How I treat splenomegaly in myelofibrosis. Blood Cancer J. 2011; 1(10):e37.CrossRefGoogle Scholar
Bell, RL et al. A ten-year, single institution experience with laparoscopic splenectomy. JSLS. 2005 Apr–Jun; 9(2):163–168.Google ScholarPubMed
Harris, W, Marcaccio, M. Incidence of portal vein thrombosis after laparoscopic splenectomy. Can J Surg. 2005 Oct; 48(5):352–354.Google Scholar
Krauth, MT et al. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention–an unresolved issue. Haematologica. 2008; 93(8):1227–1232.CrossRefGoogle ScholarPubMed
Winslow, ER, Brunt, LM. Perioperative outcomes of laparoscopic versus open splenectomy: A meta-analysis with an emphasis on complications. Surgery. 2003; 134(4):647–653.CrossRefGoogle ScholarPubMed
Dindo, D et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 August; 240(2):205–213.Google Scholar
Patel, NY et al. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg. 2012; 204(6):1014–1020.CrossRefGoogle ScholarPubMed
Bhandharkar, DS, Katara, AN, Mittal, G, Shah, R, Udwadia, TE. Prevention and management of complications of laparoscopic splenectomy. Ind J Surg. 2011;73(5):324–330.CrossRefGoogle Scholar
Kristenssen, SY et al. Long-term risks after splenectomy among 8,149 cancer-free U.S. veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99:392–398.Google Scholar
Thomsen, R, Schoonen, M, Farkas, DK, Rils, A, Jacobsen, J, Fryzek, J, Sorensen, HT. Risk of hospital contact with infection in patients with splenectomy: a population based cohort study. Ann Intern Med. 2009; 151(8):546–556.Google Scholar
Svensson, M, Wiren, M, Kimby, E, Hagglund, H. Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological disease. Eur J Haematol. 2006; 77(3):203–209.CrossRefGoogle Scholar
Vecchio, R, Cacciola, E, Cacciola, RR, Marchese, S, Intagliata, E. Portal vein thrombosis after laparoscopic and open splenectomy. J Laparoendosc Advanc Surg Techniq. 2011; 21(1):71–75.CrossRefGoogle ScholarPubMed
James, AW, Rabl, C, Westphalen, A, Fogarty, P, Posselt, A, Campos, G. Portomesenteric venous thrombosis after laparoscopic surgery; a systematic literature review. JAMA Surg. 2009; 144(6):520–526.Google Scholar
Danno, K et al. Splanchnic vein thrombosis: new risk factors and management. Surgery. 2009; 145(5):457–464.Google Scholar
Crary, SE, Buchanan, GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009; 114(14):2861–2868.Google Scholar
Donadini, MP et al. Splanchnic vein thrombosis: new risk factors and management. Thromb Res. 2012; 129(1):S93–S96.Google Scholar
Hayag-Barin, JE, Smith, R, Tucker, FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998; 57:82–84.Google Scholar
Troendle, SB, Adix, L, Crary, SE, et al. Laboratory markers of thrombosis risk in children with hereditary spherocytosis. Pediatr Blood Cancer. 2007; 49:781–785.Google Scholar
Keenan, RD, Boswell, T, Milligan, DW. Do post-splenectomy patients take prophylactic penicillin? Br J Haematol. 1999; 105:509–510.Google ScholarPubMed
Grohskopf, LA, Sokolow, LZ, Broder, KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 Influenza Season. MMWR Recomm Rep. 2017;66(No. RR-2):1–20. DOI: 10.15585/mmwr.rr6602a1Google Scholar
Rubin, LG, Schaffner, W. Care of the asplenic patient. N Engl J Med. 2014; 371:349–356.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Use of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortality Weekly Report. 2012:61(40):816.Google Scholar
Cohn, AC, MacNeil, JR, Clark, TA, Ortega-Sanchez, IR, Briere, EZ, Meissner, HC, Baker, CJ, Messonnier, NE. Prevention and control of the meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013:62(RR-2):1.Google Scholar